Immuno-oncology a “logical step” for Nanobiotix, says chief

Laurent Levy, chief executive of Nanobiotix, says branching out into immuno-oncology is a “very logical step” in the development of NBTXR3. The company’s radical new approach to radiotherapy, is unearthing some of the most promising new treatments for the killer disease, using the body’s own immune system to attack tumours and mutated cells.
Proactive Investors